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Marat Yanavitski, MDF or many cardiologists-in-training, fellowshipcan seem to be just another educational step-ping stone on the way to becoming the ex-
perts we all aspire to be. A primary purpose of this
stage in training is, of course, the acquisition of
specialized knowledge skills in cardiovascular medi-
cine. Beyond this, however, I would argue that it
also provides trainees with a critical window for
creativity that is not to be overlooked. Perhaps para-
doxically, it is the lack of expertise in a ﬁeld that
can enable fellows to discover inefﬁciencies in tools,
systems, and methods that more seasoned clinicians
have grown accustomed to working around. As
part of my fellowship education, I have been fortu-
nate to receive mentorship in cardiovascular innova-
tion from my teachers at the Cleveland Clinic and
Cleveland Clinic Innovations, its commercialization
arm. Key lessons learned from them are summarized
in Table 1.
Improvements in prevention, diagnosis, and
treatment of cardiovascular disease have allowed for
a multifold decrease in age-adjusted cardiac death
rates since the 1950s (1), much of which has been
directly related to the incorporation of disruptive
tools and techniques. From introduction of the intra-
aortic balloon pumps pioneered by Kantrowitz et al.
(2), deﬁbrillators promoted by Zoll, Lown, and others
(3,4), coronary angiography developed by Sones (5)
in the 1960s, right heart catheterization perfected
by Ganz and Swan in the 1970s (6), percutaneous
intervention developed by Grüntzig in the 1970s and
1980s (7), and transcutaneous aortic valve insertion
by Cribier et al. in the 2000s (8), to name a few,
development and adoption of novel tools have
allowed for remarkable progress in outcomes of
everyday patient care. Many of these innovationsFrom the Department of Cardiovascular Medicine Fellowship Program,
Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio.were discovered by physicians in their early careers.
Famously, DeBakey developed his roller pump, which
later became a crucial part of the heart-lung machine,
at the age of 25 as a medical student (9).
One common feature of all of the aforementioned
medical devices, as well as many other successful
innovations, is that they all provide solutions for
important clinical problems. Hence, it is safe to say
that devices, medications, and workﬂow alterations
that meaningfully improve clinical outcomes and
patient experience are well positioned to be com-
mercially successful, as well as to help improve the
standard of care. Because physicians face patient
challenges on a daily basis, they have an excellent
insight that allows them to identify crucial issues and
deﬁne effective solutions. Therefore, it is not sur-
prising that doctors authored almost 20% of medical
device patents ﬁled in the United States between the
years 1990 and 1996. Moreover, physician patents had
a greater impact on subsequent inventive activity
than nonphysician patents (10).
Another crucial tool in a budding inventor’s
armamentarium is the ability to collaborate produc-
tively. Even the most versatile individual is unlikely
to possess all of the requisite skills warranted for a
successful start-up. Frequently, off-the-shelf solu-
tions to a question posed by 1 member of the team
(e.g., a physician dealing with a clinical problem) may
exist in an unrelated area of technology well-known
to another team member, such as an engineer or in-
formation technology professional. This allows for
faster, more cost-effective development. Alterna-
tively, limitations that may seem to be an unavoid-
able part of a tool or process by some participants
could be recognized as historical and arbitrary to
those with different backgrounds. Additionally,
products developed for use in medicine and health
care may have a broader potential utility in other
areas of human endeavor, maximizing the possible
impact of a given solution. Finally, commercialization
TABLE 1 Strategies for Successful Innovations in Cardiology
Strategy Example of an Approach
Focus on patient-centered solutions Identify and address challenges patients face
Collaborate as a part of a multidisciplinary team Seek out like-minded engineers, scientists, and business executives to help address
clinical problems
Engage well-known as well as newly arising challenges Test established notions against the current understanding of processes
Understand how to utilize existing resources Reach out to a technology transfer ofﬁce, consider grant options
Rationally deal with failure Accept reality, alter idea to useful form
Strategies and examples for cardiologists to address new and long-standing patient challenges.
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524expertise is crucial in helping to raise development
funds, organize the workﬂow, identify the scope of
the solution, decide on licensing a technology, de-
velop collaboration, or spin off a new company.
As fellows in training aspire to have academic
careers, it is useful to understand the crucial role
that academic institutions can play in new tech-
nology development. Most nonproﬁt universities,
teaching hospitals, and research laboratories have
technology transfer ofﬁces. In many cases, these
ofﬁces have been focused on maximizing revenue
through intellectual property creation and patent
licensing (11). However, this strategy can be limited
by a costly and convoluted patenting process, a need
to predict solutions that will be successful in
the marketplace, and reliance on the goodwill of
industry partners, who may have substantial in-
vestments in alternate approaches. On the other
hand, although rare, academic spin-offs can be very
successful (12) as they de-risk novel concepts and are
able to rapidly alter approaches in response to
emerging data. Moreover, because they do not need
to focus on large market solutions and lack the
pressure to be immediately commercially viable
from shareholder or venture capital obligations, ac-
ademic start-ups can create a whole host of facili-
tating inventions. Some of these advances, although
too small to satisfy for-proﬁt market demands, can
oftentimes be crucial for enabling future innovation.
Last, support structure, including research and
development facilities, prototyping, administrative
support, fund-raising, and marketing costs, could be
shared by a number of projects supported by a
forward-looking technology transfer ofﬁce. This can
help with decreasing overhead costs, minimizing the
physician’s nonclinical involvement, and ultimately,
maximizing efﬁciency.
Another important component of an inventor’s
success is the willingness to tackle previously
established challenges. How does this apply to fel-
lows? They are facing age-old clinical problems inthe course of education, during which time it should
become habit to test any accepted truisms and pre-
conceived notions against the current understanding
of underlying processes. It is also important to con-
sider alternate uses of available modern techno-
logy, such as the use of social media in patient
education or the role that smartphones can play in
the improvement of medication compliance. As
many young physicians often have diverse under-
graduate educational backgrounds, it may be useful
to utilize their knowledge to facilitate formulation of
unorthodox solutions to problems. Additionally, as
fellows enjoy easy access to the expertise of their
advisers, they have a tremendous opportunity for
rapid idea vetting, which can help save valuable time
and resources.
Finally, it is important to understand that failure is
an option. As the founder of the online payment
processor PayPal, electric car company Tesla, and a
space transport service company SpaceX, Elon Musk
has stated, “If things are not failing, you are not
innovating enough” (13). The key is to stay open
minded and be able to accept reality if the initial di-
rection ends up being a dead end, which can allow
you to pivot the idea into a useful form.
As has been the case for the ﬁeld of cardiology
over the past 6 decades, technological progress will
continue to play an important role in molding future
clinical practice. Cardiology fellows can and should
actively participate in this process. To be able to
provide relevant innovations, inventors should focus
on patient-centered solutions, be able to effectively
collaborate as a part of a multidisciplinary team,
know how to utilize existing resources, be willing to
engage in well-known and new challenges, and most
importantly, be able to rationally deal with (and build
upon) inevitable failures.
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